Burger JA, Robak T, Demirkan F, Bairey O, et al. Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies. Leuk Lymphoma 2022 Jan 11:1-12. doi: 10.1080/10428194.2021.2020779.
PMID: 35014928